Digital Respiratory Equipment Market – Introduction
Digital respiratory devices endanger therapeutic and diagnostic devices that are connected to smartphone applications or other data collection modules. These devices are used in the treatment and monitoring of asthma, chronic obstructive pulmonary disease (COPD) and other respiratory diseases. Digital respiratory devices help deliver the correct dose of medication, while also effectively monitoring health and treatment outcomes. These technologically advanced devices allow the patient and physician to monitor, record, and monitor dose recording during treatment. Better disease management can be achieved with the help of smart respiratory devices.
Request a PDF brochure – https://www.transparencymarketresearch.com/sample/sample.php?flag=B&rep_id=71055
Digital Respiratory Devices Market – A Competitive Landscape
The global market for digital respiratory devices is very fragmented due to the presence of a large number of players. A large number of producers hold a prominent market share in their regions. Leading players in the global digital respiratory device market are Teva Pharmaceutical Industries Ltd., Propeller Health, 3M, AstraZeneca, Glenmark, Adherium Ltd., Pneuma Respiratory, Findair Sp. z o. o, Cohero Health, Inc. and Amiko Digital Health Limited. In December 2018, ResMed acquired Propeller Health. This acquisition has enabled the company to strengthen its position in digital health for COPD. In February 2019, Orion signed a partnership agreement with Propeller Health to bring new smart drugs to patients with COPD and asthma. This enabled Propeller Health to expand its presence in Europe. These key player strategies are contributing to the growth of the global respiratory market. Demand for digital respiratory devices has grown in both developed and emerging markets. Industrial players are adopting the practice of appointing independent distributors to expand their market presence. For example, in August 2018, Pneuma Respiratory, Inc. announced that Haisco Pharmaceutical had agreed to invest capital in the company. This agreement allowed Haisco Pharmaceutical to distribute Pneuma Respiratory, Inc. products. in China.
Request a sample of the digital respiratory device market: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=71055
Teva Pharmaceutical Industries Ltd.
Founded in 1901 with headquarters in Petach Tikva, Israel, Teva Pharmaceutical Industries Ltd. is one of the leading players in the market. Generic business is a key strength of the company. It also operates in the specialty medicine and OTC segments. Teva Pharmaceutical Industries operates globally, with a significant presence in the US, Europe and other parts of the world. It is present in 60 countries.
Founded in 1999 and headquartered in Cambridge, UK, AstraZeneca is one of the leading biopharmaceutical companies engaged in the design, development and commercialization of products for therapeutic areas such as respiratory, renal and metabolic, cardiovascular and oncological. The company is present in more than 100 countries, and its innovative medicines are used by millions of patients around the world.
Request for analysis of the impact of COVID19 on the digital respiratory equipment market – https://www.transparencymarketresearch.com/sample/sample.php?flag=covid19&rep_id=71055
Founded in 1977 with headquarters in Mumbai, India, Glenmark is one of the leading pharmaceutical organizations. The company has mainly focused on the development of a new chemical and new biological entity. It offers products in therapeutic areas, including dermatology, respiratory organs and oncology. Glenmark has 16 production facilities and six research and development centers in five countries.
Digital Respiratory Devices Market – Dynamics
Increase in the prevalence of respiratory diseases
According to the World Health Organization, in 2016, 251 million cases of chronic obstructive pulmonary disease were recorded worldwide. Moreover, globally, about 339 million people were affected by asthma in 2018. In addition, COPD accounts for more than 3 million deaths worldwide each year. The increase in the prevalence of asthma, COPD and other respiratory diseases is likely to boost the global market.
Pre-book Digital Respiratory Devices Market Report – https://www.transparencymarketresearch.com/checkout.php?rep_id=71055
Launch and approval of a new product
In December 2018, Teva Pharmaceutical Industries Ltd. she received approval from the Food and Drug Administration for her digital inhaler. In April 2018, Adherium Ltd. received OTC approval for the AstraZenecin Symbicort inhaler. In May 2016, Glenmark launched the first digital inhaler for COPSD and asthma. Product launches and approval by key players are expected to spur the growth of the global digital respiratory device market.
Digital Respiratory Devices Market – Segmentation
The global digital respiratory device market can be segmented based on product, application, distribution channel, and region.
More reports on the Transparency Market Research trend:
Transparency Market Research is a next-generation market intelligence service provider, offering fact-based solutions to business leaders, advisors and strategy professionals.
Our reports are one-time solutions for companies to grow, evolve and mature. Our real-time data collection methods, along with the ability to track more than one million high-growth niche products, are aligned with your goals. Detailed and protected statistical models used by our analysts offer insight into making the right decision in the shortest time span. For organizations that need specific but comprehensive information, we offer customized solutions through adhoc reports. These requirements come with the perfect combination of the right sense for a methodology for solving fact-oriented problems and leveraging existing data warehouses.
TMR believes this is a unique solution for customer-specific problems the right research methodology is key to helping companies make the right decision. “
Transparency market research
90 State Street,
Albany, NY – 12207
USA – Canada Toll Free: 866-552-3453